Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY20 results · Apr–Jun 2019
Suven Life Sciences reported revenue from operations of ₹198.99 crore and net profit of ₹26.21 crore for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 198.99 | — | — | 0.00 | — |
| Other income | 3.01 | — | — | 0.00 | — |
| Total income | 201.99 | — | — | 0.00 | — |
| Profit before tax | 55.21 | — | — | 0.00 | — |
| Net profit for the period | 26.21 | — | — | 0.00 | — |
| EPS, basic (₹) | 2.06 | — | — | 0.00 | — |
| Net margin (%) | 13.2 | — | — |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 198.99 | 191.66 | +3.8% | 253.30 | −21.4% |
| Other income | 3.01 | 8.13 | −63.0% | 3.75 | −19.9% |
| Total income | 201.99 | 199.79 | +1.1% | 257.05 | −21.4% |
| Profit before tax | 86.18 | 59.78 | +44.2% | 102.01 | −15.5% |
| Net profit for the period | 57.18 | 38.84 | +47.2% | 67.98 | −15.9% |
| EPS, basic (₹) | 4.49 | 3.05 | +47.2% | 5.34 | −15.9% |
| Net margin (%) | 28.7 | 20.3 | 26.8 |
Consolidated
- Filed with BSE
- 16 Aug 2019, 09:55 IST
- Board meeting
- 14 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Aug 2019, 09:55 IST
- Board meeting
- 14 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE